Sorrento Therapeutics Shares Outstanding 2010-2023 | SRNE
Sorrento Therapeutics shares outstanding from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Sorrento Therapeutics Annual Shares Outstanding
(Millions of Shares) |
| 2022 |
419 |
| 2021 |
295 |
| 2020 |
230 |
| 2019 |
141 |
| 2018 |
106 |
| 2017 |
70 |
| 2016 |
50 |
| 2015 |
37 |
| 2014 |
27 |
| 2013 |
15 |
| 2012 |
11 |
| 2011 |
248 |
| 2010 |
221 |
| 2009 |
152 |
Sorrento Therapeutics Quarterly Shares Outstanding
(Millions of Shares) |
| 2023-06-30 |
551 |
| 2023-03-31 |
543 |
| 2022-12-31 |
419 |
| 2022-09-30 |
452 |
| 2022-06-30 |
403 |
| 2022-03-31 |
337 |
| 2021-12-31 |
295 |
| 2021-09-30 |
299 |
| 2021-06-30 |
290 |
| 2021-03-31 |
298 |
| 2020-12-31 |
230 |
| 2020-09-30 |
258 |
| 2020-06-30 |
217 |
| 2020-03-31 |
183 |
| 2019-12-31 |
141 |
| 2019-09-30 |
140 |
| 2019-06-30 |
132 |
| 2019-03-31 |
122 |
| 2018-12-31 |
106 |
| 2018-09-30 |
117 |
| 2018-06-30 |
101 |
| 2018-03-31 |
85 |
| 2017-12-31 |
70 |
| 2017-09-30 |
77 |
| 2017-06-30 |
70 |
| 2017-03-31 |
51 |
| 2016-12-31 |
50 |
| 2016-09-30 |
67 |
| 2016-06-30 |
46 |
| 2016-03-31 |
38 |
| 2015-12-31 |
37 |
| 2015-09-30 |
37 |
| 2015-06-30 |
36 |
| 2015-03-31 |
36 |
| 2014-12-31 |
27 |
| 2014-09-30 |
29 |
| 2014-06-30 |
25 |
| 2014-03-31 |
23 |
| 2013-12-31 |
15 |
| 2013-09-30 |
14 |
| 2013-06-30 |
13 |
| 2013-03-31 |
12 |
| 2012-12-31 |
11 |
| 2012-09-30 |
12 |
| 2012-06-30 |
11 |
| 2012-03-31 |
261 |
| 2011-12-31 |
248 |
| 2011-09-30 |
248 |
| 2011-06-30 |
|
| 2011-03-31 |
247 |
| 2010-12-31 |
221 |
| 2010-09-30 |
230 |
| 2010-06-30 |
220 |
| 2010-03-31 |
219 |
| 2009-12-31 |
152 |
| 2009-09-30 |
170 |
| 2009-06-30 |
116 |
| 2009-03-31 |
102 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.013B |
$0.063B |
|
Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California.
|
